SCHEMBL23326296

SCHEMBL23326296

CCOc1cc(CC)c(OCC)cc1Br

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.52
TSHR P16473 2/20 0.50
HSD17B10 Q99714 1/20 0.50
KMT2A Q03164 2/20 0.42
MAPT P10636 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HPGD P15428 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
HTR2A P28223 3/20 0.40
HTR2C P28335 2/20 0.40
HTR2B P41595 1/20 0.40
NCOA1 Q15788 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39
TAAR1 Q96RJ0 2/20 0.39
POLB P06746 1/20 0.39
MEN1 O00255 1/20 0.37
CYP3A4 P08684 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29775469 1.00 LMNA (0.52) LMNATSHRHSD17B10KMT2AMAPT
SCHEMBL23326208 0.90 HTR2A (0.51) LMNATSHRHSD17B10HTR2AHTR2C
SCHEMBL23326239 0.90 HTR2A (0.51) LMNATSHRHSD17B10HTR2AHTR2C
SCHEMBL21757374 0.88 LMNA (0.47) LMNATSHRHSD17B10KMT2AMAPT
SCHEMBL10967724 0.87 LMNA (0.57) LMNATSHRHSD17B10KMT2AMAPT
SCHEMBL23326179 0.82 TSHR (0.50) LMNATSHRHSD17B10KMT2AMAPT
SCHEMBL16200089 0.82 LMNA (0.43) LMNATSHRHSD17B10KMT2AMAPT
SCHEMBL15980584 0.82 HTR2A (0.40) LMNATSHRHSD17B10MAPTHTR2A
SCHEMBL23586592 0.80 LMNA (0.44) LMNATSHRHSD17B10KMT2AMAPT
SCHEMBL4472996 0.79 TSHR (0.46) LMNATSHRHSD17B10KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114761083-B 5-HT for treating depression 2A Agonists 罗福拉公司 2024-02-13 CN disclosed
EP-3962601-B1 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION Lophora ApS (DK) 2023-05-31 EP disclosed
US-11642336-B2 5-HT2A agonists for use in treatment of depression Lophora ApS (DK) 2023-05-09 US disclosed
US-11633390-B2 5-HT2A agonists for use in treatment of depression Lophora ApS (DK) 2023-04-25 US disclosed
CN-114761083-A 5-HT for the treatment of depression2AAgonists 罗福拉公司 2022-07-15 CN disclosed
US-20220062257-A1 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION Lophora ApS (DK) 2022-03-03 US disclosed
US-11246860-B2 5-HT2A agonists for use in treatment of depression Lophora ApS (DK) 2022-02-15 US disclosed
US-20210330658-A1 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION Lophora ApS (DK) 2021-10-28 US disclosed
US-20210137908-A1 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION Lophora ApS (DK) 2021-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210330658-A1 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION HTR2A, HTR2C, HTR5A LMNA 3797/4885TSHR 252/4885HSD17B10 1542/4885
US-20220062257-A1 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION HTR2A, HTR2C, HTR5A LMNA 3797/4885TSHR 252/4885HSD17B10 1542/4885
US-11642336-B2 5-HT2A agonists for use in treatment of depression HTR2A, HTR2C, HTR5A LMNA 3797/4885TSHR 252/4885HSD17B10 1542/4885
US-20210137908-A1 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION HTR2A, HTR2C, HTR5A LMNA 3797/4885TSHR 252/4885HSD17B10 1542/4885
US-11633390-B2 5-HT2A agonists for use in treatment of depression HTR2A, HTR2C, HTR5A LMNA 3797/4885TSHR 252/4885HSD17B10 1542/4885
US-11246860-B2 5-HT2A agonists for use in treatment of depression HTR2A, HTR2C, HTR5A LMNA 3797/4885TSHR 252/4885HSD17B10 1542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.